The Japan working group for the assessment that the pioglitazone protects DM patients against re-infarction.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Pioglitazone (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms PPAR
- 23 May 2018 Biomarkers information updated
- 11 Jan 2012 Planned end date changed from 1 Apr 2009 to 1 May 2013 as reported by University Hospital Medical Information Network - Japan
- 04 Dec 2005 New trial record.